About the Company
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ARWR News
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms ...
ARWR Apr 2024 20.000 put
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Myszkowski sold 40,000 shares of the company's stock on March 6, 2024, according to a recent SEC filing. PASADENA, Calif., March 08, ...
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic Value
Arrowhead Pharmaceuticals is estimated to be 26% overvalued based on current share price of US$34.08 The US$55.15 analyst ...
The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips After closing out 2023 with a 15.1% gain, the Russell 2000 ...
Arrowhead Pharmaceutical Gains Over Initiation Of Phase 1/2a Study Of ARO-DM1
Shares of Arrowhead Pharmaceuticals, Inc. (ARWR) are climbing over 6 percent on Friday morning following the announcement of ...
Ionis stock jumps as MASH drug succeeds in mid-stage trial
Ionis Pharmaceuticals (NASDAQ:IONS) shares rose in early trading on Wednesday after the company reported positive results ...
Krystal Biotech confirms cancellation from Cowen conference due to CEO sickness
Krystal Biotech (NASDAQ:KRYS) earlier Tuesday canceled out of a presentation at a TD Cowen healthcare conference in Boston.
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation ...
Lipid-Nanoparticle Based Genomic Medicines Market worth $32.5 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Lipid-Nanoparticle Based Genomic Medicines ...
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday. Shares of EQT Corporation (NYSE: EQT ...
Millet Flour Market to Reach US$ 7.8 Billion by 2034, Driven by Rising Demand for Gluten-Free Alternatives
As per the latest analysis, the global millet flour market is expected to be valued at US$ 5.1 billion in 2024. It will likely exhibit steady growth, with millet flour sales growing at a CAGR of 5.3% ...
Lexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended December 31, 2023 and provided an update on key corporate milestones. "2023 was a pivotal year ...
Loading the latest forecasts...